Pediatrix Medical Group (NYSE:MD) Now Covered by Macquarie

Macquarie began coverage on shares of Pediatrix Medical Group (NYSE:MD) in a report released on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $18.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. UBS Group upped their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, December 11th. Truist Financial upped their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Jefferies Financial Group lifted their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $16.42.

Pediatrix Medical Group Price Performance

NYSE:MD opened at $14.46 on Monday. The stock’s fifty day moving average is $14.02 and its two-hundred day moving average is $10.83. The company has a market capitalization of $1.24 billion, a P/E ratio of -4.73, a P/E/G ratio of 2.00 and a beta of 1.57. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The business had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.29 earnings per share. Equities analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current year.

Insider Buying and Selling

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by insiders.

Institutional Trading of Pediatrix Medical Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Aristeia Capital L.L.C. purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at about $687,000. Rubric Capital Management LP grew its position in Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after acquiring an additional 7,241,400 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Pediatrix Medical Group by 14.1% during the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock valued at $5,953,000 after purchasing an additional 63,581 shares during the period. Weiss Asset Management LP lifted its position in shares of Pediatrix Medical Group by 50.5% during the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after purchasing an additional 306,143 shares in the last quarter. Finally, ClariVest Asset Management LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at $1,721,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.